Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  American Society of Nephrology. Clinical Journal

• Publication date

  2010-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2215/CJN.03360410PMID 20847094PMCID PMC2994082
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• S100A12 Mediates Aortic Wall Remodeling and Aortic Aneurysm

  2010cited by this paper
• Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease.

  2010influential reference
• Cardiovascular and noncardiovascular mortality among patients starting dialysis.

  2009cited by this paper
• Avoiding infinite estimates of time‐dependent effects in small‐sample survival studies

  2008cited by this paper
• Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients

  2008cited by this paper
• Increased Plasma S100A12 (EN-RAGE) Levels in Hemodialysis Patients with Atherosclerosis

  2008cited by this paper
• Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?

  2008cited by this paper
• Receptor for advanced glycation end products--soluble form and gene polymorphisms in chronic haemodialysis patients.

  2007influential reference
• Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite.

  2007cited by this paper
• S100A12 provokes mast cell activation: a potential amplification pathway in asthma and innate immunity.

  2007cited by this paper
• Low Circulating Endogenous Secretory Receptor for AGEs Predicts Cardiovascular Mortality in Patients With End-Stage Renal Disease

  2007cited by this paper
• Soluble receptor for advanced glycation end products in patients with decreased renal function.

  2006cited by this paper
• Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein.

  2006cited by this paper
• Advanced glycation end products in renal failure.

  2006cited by this paper
• Enhanced RAGE-mediated NFκB stimulation in inflamed hemodialysis patients

  2005cited by this paper
• Plasma Levels of Soluble Receptor for Advanced Glycation End Products and Coronary Artery Disease in Nondiabetic Men

  2005cited by this paper
• Enhanced RAGE-mediated NFkappaB stimulation in inflamed hemodialysis patients.

  2005cited by this paper
• Low-molecular-weight AGEs are associated with GFR and anemia in patients with type 2 diabetes.

  2004cited by this paper
• Morphologic Findings of Coronary Atherosclerotic Plaques in Diabetics: A Postmortem Study

  2004cited by this paper
• Serum levels of total homocysteine, homocysteine metabolites and of advanced glycation end-products (AGEs) in patients after renal transplantation.

  2003cited by this paper
• RAGE Blockade Stabilizes Established Atherosclerosis in Diabetic Apolipoprotein E–Null Mice

  2002cited by this paper
• The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses.

  2001influential reference
• A Solution to the Problem of Monotone Likelihood in Cox Regression

  2001cited by this paper
• Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice.

  2001cited by this paper
• Proinflammatory properties of the human S100 protein S100A12

  2001cited by this paper
• RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides.

  1999cited by this paper
• Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts

  1998cited by this paper
• Advanced Glycation End Products-driven Angiogenesis in Vitro

  1997cited by this paper
• The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis.

  1996cited by this paper
• Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products.

  1993cited by this paper
• Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins.

  1992cited by this paper
• Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications.

  1988influential reference
• Predicting nutrition-associated complications for patients undergoing gastrointestinal surgery.

  1987cited by this paper
• 0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(11):5423–5428 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2003-032223

  year unknowncited by this paper

• Elevated acute-phase plasma levels of S100A12 [EN-RAGE] are associated with vascular recurrence after ischemic stroke.

  2026cites this paper
• Osteoprotegerin as a Marker of Cardiovascular Events in Patients with Chronic Kidney Disease

  2025cites this paper
• Development and validation of a comprehensive machine learning framework for a diagnostic model of uremia based on genes involved in major depressive disorder

  2025cites this paper
• Neutrophil extracellular trap is an important connection between hemodialysis and acute myocardial infarction

  2023cites this paper
• Study of Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation

  2023cites this paper
• Therapeutic targeting of chronic kidney disease-associated DAMPs differentially contributing to vascular pathology

  2023cites this paper
• RAGE/DIAPH1 and atherosclerosis through an evolving lens: Viewing the cell from the “Inside – Out”

  2023cites this paper
• Effects of Short- And Medium-Term Exposures to Lower Air Temperature on 71 Novel Biomarkers of Subclinical Inflammation: Results from the KORA F4 Study

  2023cites this paper
• Impact of medium cut‐off membranes on S100A12 and soluble receptor for advanced glycation end products

  2022cites this paper
• Molecular markers for early stratification of disease severity and progression in COVID-19

  2022cites this paper
• The role of advanced glycation end products in patogenesis of diabetic nephropathy

  2022cites this paper
• S100A12 as Biomarker of Disease Severity and Prognosis in Patients With Idiopathic Pulmonary Fibrosis

  2022cites this paper
• Role of RAGE and its ligand HMGB1 in the development of COPD

  2022cites this paper
• Targeting Scavenger Receptors in Inflammatory Disorders and Oxidative Stress

  2022cites this paper
• The use of the soluble receptor for advanced glycation-end products (sRAGE) as a potential biomarker of disease risk and adverse outcomes

  2021cites this paper
• Circulating Plasma Biomarkers in Biopsy-Confirmed Kidney Disease: Results from the Boston Kidney Biopsy Cohort

  2021cites this paper
• Circulating Advanced Glycation End Products and Their Soluble Receptors in Relation to All-Cause and Cardiovascular Mortality: A Systematic Review and Meta-analysis of Prospective Observational Studies.

  2021cites this paper
• Circulating Plasma Biomarkers in Biopsy-Confirmed Kidney Disease

  2021cites this paper
• Serum and Tissue Levels of Advanced Glycation End Products and Risk of Mortality in Patients on Maintenance Hemodialysis

  2021cites this paper
• Osteoprotegerin is a marker of cardiovascular mortality in patients with chronic kidney disease stages 3–5

  2021cites this paper
• Cerebro-Cardiovascular Diseases

  2020cites this paper
• The role of soluble receptor for advanced glycation end-products (sRAGE) in the general population and patients with diabetes mellitus with a focus on renal function and overall outcome

  2020cites this paper
• S100 family proteins in inflammation and beyond.

  2020cites this paper
• Increased levels of soluble Receptor for Advanced Glycation End-products (RAGE) are associated with a higher risk of mortality in frail older adults.

  2019cites this paper
• S100 Proteins in Atherosclerosis.

  2019cites this paper
• Chronic Inflammation and S 100 A 12 / Receptor for Advanced Glycation Endproducts Axis : A

  2019cites this paper
• Receptor for advanced glycation end products: a key molecule in the genesis of chronic kidney disease vascular calcification and a potential modulator of sodium phosphate co-transporter PIT-1 expression.

  2019cites this paper
• G82S polymorphism of receptor for advanced glycation end products gene and serum soluble RAGE levels in mild cognitive impairment and dementia of Alzheimer's type patients in Turkish population.

  2019cites this paper
• Role of the Soluble Receptor for Advanced Glycation End Products (sRAGE) as a Prognostic Factor for Mortality in Hemodialysis and Peritoneal Dialysis Patients

  2018cites this paper
• The Role of Advanced Glycation End Products in Aging and Metabolic Diseases: Bridging Association and Causality.

  2018cites this paper
• Effects of S100A12 gene silencing on serum levels of anti‐inflammatory/pro‐inflammatory cytokines in septic rats through the ERK signaling pathway

  2018influential citation
• Acute effects of haemodialysis on circulating microparticles

  2018cites this paper
• Polymorphisms of the receptor for advanced glycation end products and glyoxalase I and long-term outcome in patients with breast cancer

  2017cites this paper
• S100A12 in renal and cardiovascular diseases

  2017cites this paper
• Dialysis initiation and clinical outcomes in chronic kidney disease : role of education and biomarkers

  2016cites this paper
• The Receptor for Advanced Glycation End Products (Rage) and Its Ligands in Plasma and Infrainguinal Bypass Vein.

  2016cites this paper
• Effects on the Removal of Uremic Toxins

  2016cites this paper
• [Examination of skin autofluorescence for the determination of glycation end-products in patients on chronic hemodialysis].

  2016cites this paper
• Associations between Soluble Receptor for Advanced Glycation End Products (sRAGE) and S100A12 (EN-RAGE) with Mortality in Long-term Hemodialysis Patients

  2016influential citation
• Interaction of β1-adrenoceptor with RAGE mediates cardiomyopathy via CaMKII signaling.

  2016cites this paper
• Elevated Circulating S100A12 Associates with Vascular Disease and Worse Clinical Outcome in Peritoneal Dialysis Patients

  2016cites this paper
• Peeling Away Better Than Fishing Around Later!

  2016cites this paper
• Circulating S100A12 Levels Are Associated with Progression of Abdominal Aortic Calcification in Hemodialysis Patients

  2016cites this paper
• Glucose degradation products in patients on hemodialysis : interventional studies

  2016cites this paper
• Serum S100A12: A Risk Marker or Risk Factor of Vascular Calcification in Chronic Kidney Disease?

  2015cites this paper
• S100A12 and the S100/Calgranulins: Emerging Biomarkers for Atherosclerosis and Possibly Therapeutic Targets.

  2015cites this paper
• Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients.

  2015influential citation
• The receptor for advanced glycation end products and risk of peripheral arterial disease, amputation or death in type 2 diabetes: a population-based cohort study

  2015cites this paper
• Do elevated plasma S100A12 levels predict atherosclerosis in peritoneal dialysis patients?

  2015influential citation
• Serum S100A12 and Progression of Coronary Artery Calcification Over 4 Years in Hemodialysis Patients

  2015cites this paper
• Usefulness of S100A12 as a prognostic biomarker for adverse events in patients with heart failure.

  2015cites this paper
• S100A12 and the S100/CalgranulinsSignificance

  2015cites this paper
• Skin autofluorescence advanced glycosylation end products as an independent predictor of mortality in high flux haemodialysis and haemodialysis patients

  2015cites this paper
• The Impact on Multiple Ligands for Receptor of Advanced Glycation End Products with Linagliptin

  2015cites this paper
• Advanced glycation end product accumulation: a new enemy to target in chronic kidney disease?

  2014cites this paper
• EN-RAGE: A Novel Inflammatory Marker for Incident Coronary Heart Disease

  2014cites this paper
• Plasma levels of the pro-inflammatory protein S100A12 (EN-RAGE) are associated with muscle and fat mass in hemodialysis patients: a cross-sectional study

  2014influential citation
• Chronic sustained inflammation links to left ventricular hypertrophy and aortic valve sclerosis: a new link between S100/RAGE and FGF23.

  2014cites this paper
• Calgranulins may contribute vascular protection in atherogenesis.

  2014cites this paper
• The peptidic middle molecules: is molecular weight doing the trick?

  2014cites this paper
• Plasma S100A12 is associated with functional outcome after ischemic stroke: Research for Biomarkers in Ischemic Stroke.

  2014cites this paper
• Association between Angiotensin Converting Enzyme Insertion/Deletion Polymorphism and Soluble Receptor of Advanced Glycation End Products in Type 2 Diabetic Patients with and without Microalbuminuria

  2014cites this paper
• The axis AGE-RAGE-soluble RAGE and oxidative stress in chronic kidney disease.

  2014cites this paper
• S100/Calgranulin-Mediated Inflammation Accelerates Left Ventricular Hypertrophy and Aortic Valve Sclerosis in Chronic Kidney Disease in a Receptor for Advanced Glycation End Products–Dependent Manner

  2014cites this paper
• Low Glucose Degradation Product Peritoneal Dialysis Regimen Is Associated With Lower Plasma EN‐RAGE and HMGB‐1 Proinflammatory Ligands of Receptor for Advanced Glycation End Products

  2014cites this paper
• S100A12 and Soluble Receptor for Advanced Glycation End Products Levels During Human Severe Sepsis

  2013cites this paper
• Changes in circulating biomarkers during a single hemodialysis session

  2013cites this paper
• S100A12 Gene Expression Is Increased in Peripheral Leukocytes in Chronic Kidney Disease Stage 4-5 Patients with Cardiovascular Disease

  2013cites this paper
• Prognostic utility of plasma S100A12 levels to establish a novel scoring system for predicting mortality in maintenance hemodialysis patients: a two-year prospective observational study in Japan

  2013cites this paper
• Calcitriol treatment increases serum levels of the soluble receptor of advanced glycation end products in hemodialysis patients with secondary hyperparathyroidism.

  2013cites this paper
• The AGE-RAGE pathway and its relation to cardiovascular disease in patients with chronic kidney disease.

  2013cites this paper
• Circulating levels of soluble receptor for advanced glycation end product are inversely associated with vascular calcification in patients on haemodialysis independent of S100A12 (EN‐RAGE) levels

  2013influential citation
• The AGEeRAGE Pathway and Its Relation to Cardiovascular Disease in Patients with Chronic Kidney Disease

  2013cites this paper
• Soluble receptor for advanced glycation end products predicts 28-day mortality in critically ill patients with sepsis

  2013cites this paper
• Role of Advanced Glycation Endproducts and Potential Therapeutic Interventions in Dialysis Patients

  2012cites this paper
• Cardiovascular biomarkers in chronic kidney disease.

  2012cites this paper
• EN-RAGE (extracellular newly identified receptor for advanced glycation end-products binding protein) and mortality of long-term hemodialysis patients: A prospective observational cohort study.

  2012cites this paper
• Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis.

  2012cites this paper
• Serum S100A12 (EN-RAGE) Levels in Patients with Decreased Renal Function and Subclinical Chronic Inflammatory Disease

  2011cites this paper
• Protein-Energy Wasting and Mortality in Chronic Kidney Disease

  2011cites this paper
• Inflammation as a risk factor and target for therapy in chronic kidney disease

  2011cites this paper
• The Receptor for Advanced Glycation End-Products (RAGE) and its Ligands in Systemic Inflammation following Surgery Necessitating Cardiopulmonary Bypass

  2011cites this paper
• Endogenous Secretory Receptor for Advanced Glycation End Products and Chronic Kidney Disease in the Elderly Population

  2011cites this paper
• Chronic Inflammation and S100A12/ Receptor for Advanced Glycation Endproducts Axis: A Novel Risk Factor for Cardiovascular Disease in Patients with Chronic Kidney Disease?

  2011cites this paper
• Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease

  2011cites this paper
• Vascular Remodeling and Arterial Calcification Are Directly Mediated by S100A12 (EN-RAGE) in Chronic Kidney Disease

  2011cites this paper
• Plasma S100A12 Levels and Peripheral Arterial Disease in End-Stage Renal Disease

  2011cites this paper
• S100/calgranulins EN-RAGEing the blood vessels: implications for inflammatory responses and atherosclerosis.

  2011cites this paper
• Effects of S 100 A 12 gene silencing on serum levels of anti-inflammatory / pro-inflammatory cytokines in septic rats through the ERK signaling pathway

  year unknowninfluential citation